---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-061061"
form_type: "8-K"
ticker: "REVB"
cik: "0001810560"
company_name: "REVELATION BIOSCIENCES, INC."
filed_at: "2024-05-16T23:59:59+00:00"
generated_at: "2026-06-01T21:36:04.761006+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Revelation Bio shareholders approve director elections, equity plan increase, auditor ratification

## Summary
- James Rolke (122,822 for) and Jess Roper (122,543 for) elected as Class B directors; 461,538 broker non-votes.
- Approved amendment to 2021 Equity Incentive Plan increasing reserved shares from 21,623 to 163,294 (107,447 for, 42,981 against).
- Ratified Baker Tilly US, LLP as auditor for FY2024 with 595,879 for, 18,558 against.
- Quorum achieved with 614,695 shares present (greater than 1/3 of 1,632,935 outstanding shares).

## SEC filing metadata
- accession: 0000950170-24-061061
- form_type: 8-K
- ticker: REVB
- cik: 0001810560
- company_name: REVELATION BIOSCIENCES, INC.
- filed_at: 2024-05-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1810560/000095017024061061/0000950170-24-061061-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1810560/000095017024061061/revb-20240515.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-061061
- JSON: https://secwatch.observer/filing/0000950170-24-061061.json
- Plain text: https://secwatch.observer/filing/0000950170-24-061061.txt

## Source-grounded claims
- claim_id: 57aaaf787f3e058f539081e8a6174950fe64e03d
  claim: REVELATION BIOSCIENCES, INC. shareholders approved Approval to increase the number of shares reserved under the Company's 2021 Equity Incentive Plan from 21,623 to 163,294.
  evidence_excerpt: Stockholders approved an amendment to the 2021 Equity Incentive Plan to increase the number of shares reserved under the 2021 Equity Incentive Plan from 21,623 to 163,294, based on the votes listed below: For Against Abstain 107,447 42,981 2,729 There were 461,538 broker non-votes regarding this proposal.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1810560/000095017024061061/0000950170-24-061061-index.htm
- claim_id: 71588b43d923376f821b065125c00b60a7dcf7e0
  claim: REVELATION BIOSCIENCES, INC. shareholders approved Ratification of Baker Tilly US, LLP as auditor for fiscal year ending December 31, 2024 at the 2024-12-31 meeting.
  evidence_excerpt: Stockholders ratified Baker Tilly US, LLP to audit our financial statements for the fiscal year ending December 31, 2024, based on the votes listed below: For Against Abstain 595,879 18,558 258 There were no broker non-votes regarding this proposal.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1810560/000095017024061061/0000950170-24-061061-index.htm
- claim_id: 7aa965fd16aed83aa833154c40394a0d1372c04a
  claim: REVELATION BIOSCIENCES, INC. shareholders approved Election of two nominees for Class B director: James Rolke and Jess Roper.
  evidence_excerpt: Stockholders approved to elect the two nominees for Class B director named herein to serve until the 2027 Annual Meeting or their successors are duly elected and qualified, based on the votes listed below: Director Nominee For Against Abstain James Rolke 122,822 23,715 6,620 Jess Roper 122,543 27,978 2,636 There were 461,538 broker non-votes regarding the election of directors.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1810560/000095017024061061/0000950170-24-061061-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.